ABAngela R. Bradbury

Angela R. Bradbury

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Angela R. Bradbury has a total of 402 co-authors. Here are the top co-authors by number of shared publications:

  • Brian L. Egleston

    Fox Chase Cancer Center, Philadelphia, USA

    16 shared publications
  • Susan M. Domchek

    University of Pennsylvania, Division of Hematology-Oncology

    15 shared publications
  • Dominique Fetzer

    The University of Pennsylvania, Abramson Cancer Center and Division of Hematology-Oncology, Philadelphia, PA, USA

    14 shared publications
  • Jacquelyn Powers

    Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, USA

    10 shared publications
  • Linda Patrick-Miller

    Angela R. Bradbury, Kara N. Maxwell, Laura DiGiovanni, Jamie Brower, Dominique Fetzer, Jill Bennett Gaieski, Amanda Brandt, Danielle McKenna, Jessica Long, Jacquelyn Powers, Jill E. Stopfer, Katherine L. Nathanson, and Susan M. Domchek, Perelman School of Medicine at the University of Pennsylvania; Brian L. Egleston, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA; and Linda Patrick-Miller, The University of Chicago, Chicago, IL

    9 shared publications
  • Susan M. Domchek

    Basser Center for BRCA, University of Pennsylvania, Philadelphia, PA, USA

    9 shared publications

Latest Publications

  • Open Access

    A randomized study of digital versus genetic counselor return of actionable genetic research results to biobank participants (RESPECT3 study)

    by Anuja Rajendra Godbole, Elisabeth Wood, Brian Egleston, Lily Hoffman-Andrews, Sarah Brown, Sarah Howe, Sanjana Shastri, Rajia Mim, Justin Feng, Anjali Owens, et al.

    There is consensus that research participants should be informed about plans for return of genetic research results. However, best practices for return of

  • Open Access

    CONNECT 4 APOE : A randomized study of phone versus videoconference delivery of APOE genotype disclosure in the Generation Study

    by Angela R. Bradbury, Brian L Egleston, Elisabeth Wood, Jason Karlawish, J. Scott Roberts, Scott Kim, Cara Cacioppo, Laura Eppelmann, Michelle Weinberg, Demetrios Ofidis, et al.

    Background: APOE genotyping is increasingly important to identify candidates eligible for Alzheimer's prevention trials. Such testing is also now commonplace for patients considering new anti‐amyloid treatments, given that APOE4 carriers are at elevated risk for treatment side effects. Data to inform best practices for sharing APOE results are needed. Method: CONNECT4 is a multi‐center, randomized trial (NCT02978729) comparing disclosure of APOE4 genotype by remote videoconference (VD) or telephone (TD) with a genetic counselor in cognitively unimpaired adults 60‐75 YO. It was ancillary to the Generation 1 prevention trial, enrolling at 20 US sites. Patient‐reported outcomes (PROs) were collected at 2‐7 days (T1), 6 weeks (T2), and 6 months (T3) following APOE4 disclosure. Primary outcomes were change in genetic knowledge and disease‐specific distress (T0‐T1) and satisfaction (T1). We used T‐tests and Fisher's exact tests to compare arms and carrier groups. Result: 274 participants were randomized to TD and 267 to VD. Of those with complete data ( n = 409, 76%), the mean age was 67.1 YO, 64.1% were female, 92.2% were white; 77.8% reported a family history of AD and 29.8% were APOE4 homozygotes, 40.4% were heterozygotes and 29.8% were noncarriers. There were no significant differences among arms in knowledge or distress, but slightly higher satisfaction with TD (Table 1). There were no significant differences in secondary PROs. By genotype, the only differences by arm included change in perceived lifetime numerical risk from T0‐T1 among homozygotes (TD ‐5.19 v. VD +4.07, p = 0.018), and T0‐T2 among noncarriers (TD ‐13.33 v. VD ‐22.28, p = 0.053) and satisfaction with genetic services among heterozygotes (TD 40.46 v VD 38.65, p = 0.01). In analyses evaluating moderators of PROs that adjusted for result, state anxiety increased under TD and decreased under VD for non‐White participants (T0‐T1), but declined by a similar amounts under both modalities for White participants ( p = 0.039). Conclusion: Both telephone and videoconference are reasonable options for disclosure of APOE results in cognitively unimpaired individuals across all genotypes. While satisfaction was slightly higher with TD, small differences in numerical perceived risk by genotype and reductions in state anxiety among non‐white participants, suggest potential small benefits to VD for some subgroups.

  • Open Access

    CONNECT 4 APOE : A randomized study of phone versus videoconference delivery of APOE genotype disclosure in the Generation Study

    by Angela R. Bradbury, Brian L Egleston, Elisabeth Wood, Jason Karlawish, J. Scott Roberts, Scott Kim, Cara Cacioppo, Laura Eppelmann, Michelle Weinberg, Demetrios Ofidis, et al.

    Background: APOE genotyping is increasingly important to identify candidates eligible for Alzheimer's prevention trials. Such testing is also now commonplace for patients considering new anti‐amyloid treatments, given that APOE4 carriers are at elevated risk for treatment side effects. Data to inform best practices for sharing APOE results are needed. Method: CONNECT4 is a multi‐center, randomized trial (NCT02978729) comparing disclosure of APOE4 genotype by remote videoconference (VD) or telephone (TD) with a genetic counselor in cognitively unimpaired adults 60‐75 YO. It was ancillary to the Generation 1 prevention trial, enrolling at 20 US sites. Patient‐reported outcomes (PROs) were collected at 2‐7 days (T1), 6 weeks (T2), and 6 months (T3) following APOE4 disclosure. Primary outcomes were change in genetic knowledge and disease‐specific distress (T0‐T1) and satisfaction (T1). We used T‐tests and Fisher's exact tests to compare arms and carrier groups. Result: 274 participants were randomized to TD and 267 to VD. Of those with complete data ( n = 409, 76%), the mean age was 67.1 YO, 64.1% were female, 92.2% were white; 77.8% reported a family history of AD and 29.8% were APOE4 homozygotes, 40.4% were heterozygotes and 29.8% were noncarriers. There were no significant differences among arms in knowledge or distress, but slightly higher satisfaction with TD (Table 1). There were no significant differences in secondary PROs. By genotype, the only differences by arm included change in perceived lifetime numerical risk from T0‐T1 among homozygotes (TD ‐5.19 v. VD +4.07, p = 0.018), and T0‐T2 among noncarriers (TD ‐13.33 v. VD ‐22.28, p = 0.053) and satisfaction with genetic services among heterozygotes (TD 40.46 v VD 38.65, p = 0.01). In analyses evaluating moderators of PROs that adjusted for result, state anxiety increased under TD and decreased under VD for non‐White participants (T0‐T1), but declined by a similar amounts under both modalities for White participants ( p = 0.039). Conclusion: Both telephone and videoconference are reasonable options for disclosure of APOE results in cognitively unimpaired individuals across all genotypes. While satisfaction was slightly higher with TD, small differences in numerical perceived risk by genotype and reductions in state anxiety among non‐white participants, suggest potential small benefits to VD for some subgroups.

  • Open Access

    A Randomized Hybrid Type I Effectiveness-Implementation Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer (eREACH2): study protocol

    by E Mastaglio, B Egleston, Kimberley Lee, D Fetzer, S Brown, S Domchek, Linda Fleisher, K Wen, L Wagner, J Roberts, et al.

    Background: Germline cancer genetic testing has become a standard evidence-based practice, with established risk reduction and cancer screening guidelines for genetic carriers. There are also targeted treatments for some genetic carriers with cancers such as breast and ovarian cancer. Yet, many at-risk patients do not have access to genetic services, leaving many genetic carriers unidentified. The eREACH 2 study (A Randomized Hybrid Type I Effectiveness-Implementation Study of an eReach Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer) evaluates whether an interactive, patient-centered digital alternative for genetic education and disclosure of results is non-inferior compared to the traditional model of pre-and post-test counseling with a genetic counselor. Methods: This is a Hybrid Type 1 effectiveness implementation study in which participants are randomized using a 2×2 design to test a self-directed, patient-informed, digital intervention to deliver clinical genetic testing versus the traditional pre-test (visit 1) and post-test (visit 2: disclosure) counseling delivered by a genetic counselor. The 4 arms include A) genetic counselor for visit 1 and visit 2, B) genetic counselor for visit 1 and digital intervention for visit 2, C) digital intervention for visit 1 and genetic counselor for visit 2, and D) digital intervention for both visits. Participants are adults who meet National Comprehensive Cancer Network and/or American Society of Clinical Oncology guidelines for germline genetic testing and are recruited from both community and medical sites across the United States by way of clinician referral as well as patient self-referral. The primary outcomes are non-inferiority in uptake of genetic testing and change in genetic knowledge and general anxiety from baseline to post-disclosure. Discussion: With many barriers to accessing genetic services, innovative delivery models are needed to address these gaps and increase uptake of genetic services. The eREACH2 study evaluates the effectiveness of an interactive patient-centered digital intervention to deliver clinical genetic testing. We expect this work will inform evidence-based guidelines and the standard-of-care for delivery of genetic testing and is designed to be broadly applicable and easily adaptable for other populations and settings even beyond oncology (e.g. Alzheimer’s disease). Trial registration: This protocol was registered at clinicaltrials.gov ( NCT05427240 ) on 6/7/2022.


  • Open Access

    An electronic review of clinical outcomes after return of actionable genetic research results from a health system research biobank

    by Giorgio Cocchella, Lillian Phung, Elisabeth Wood, Brian Egleston, Lily Hoffman-Andrews, Sarah Brown, Demetrios Ofidis, Rajia Mim, Hannah Griffin, Dominique Fetzer, et al.


  • Open Access

    The MyCancerGene study: a hybrid type 1 effectiveness-implementation randomized study comparing a patient-centered digital genetic health portal to usual care after receipt of cancer genetic testing

    by Daniel Chavez-Yenter, Dominique Fetzer, Brian Egleston, Susan Domchek, Linda Fleisher, Lynne I. Wagner, Kuang-Yi Wen, Kelsey Karpink, Lauren Gutstein, Shelby Posen, et al.

    Genetic testing has become more complex with the transition from single gene testing to multi-gene panels and whole-exome sequencing. The adoption of more complex genetic testing and the promise of precision medicine has created a critical and urgent need for longitudinal clinical follow-up with patients who undergo cancer genetic testing given the residual uncertainty. There is an increasing need for multidisciplinary translational research that focuses on how to advance precision medicine discoveries into clinical practice and to capitalize on connectivity (e.g. digital health) interventions in ways that optimize cancer risk reducing behaviors in real-world clinical populations. The overall goal of this Hybrid Type 1 effectiveness-implementation randomized study is to evaluate the effectiveness of the MyCancerGene intervention to improve longitudinal (short-term and long-term) understanding (e.g. knowledge) and reactions to (e.g. anxiety) clinical genetic testing compared to usual care. We hypothesize that access to MyCancerGene will be associated with short-term and post-disclosure increases in knowledge, decreases in distress, increases in communication with relatives and health care providers and performance of risk reducing health behaviors compared to usual care. Equally important, we hypothesize that our implementation process evaluation will inform recommendations for future adaptation and sustainability for other precision medicine applications. Given the increasing complexity of genetic testing applications (e.g. multi-gene testing, whole exome sequencing) and the need for post-disclosure follow-up, we expect this study to inform evidence-based practice guidelines for delivery of genetic medicine and potentially change the paradigm to include longitudinal care in precision medicine. To address the clinically significant gap in the delivery of genetic medicine, patient and provider stakeholder input have been used to develop a patient and provider informed centered genetic digital health portal to enhance patient understanding of, and affective and behavioral responses to genetic testing, particularly in the era of evolving evidence and risk information. This protocol was registered at clinicaltrials.gov (NCT04774445) in February 18, 2021.


  • Open Access

    eREACH: A randomized trial of digital alternatives to genetic counseling for metastatic cancer

    by Kimberley T. Lee, Brian Egleston, Briana McLeod, Sarah Brown, Sarah Howe, Dominique Fetzer, Susan M. Domchek, Lauren Gutstein, Cara Cacioppo, Dana Clark, et al.

    With FDA approval of targeted therapies in patients with germline BRCA1/2-related advanced cancers there is a need to evaluate efficient and effective delivery models for germline cancer genetic testing. We sought to evaluate the effectiveness of replacing traditional pretest and posttest counseling with a genetic counselor (GC) with a digital intervention in patients with metastatic cancers. eREACH is a 4-arm randomized non-inferiority trial with a 2×2 design conducted from 2020-2024 and participants were followed for 6 months. Participants were recruited from the community and academic and community medical sites across the United States. A referred sample of adults with advanced or metastatic breast, prostate, ovarian or pancreatic cancer. The digital pretest intervention consists of 8 modules including purpose of genetic testing and implications of results. The digital post-test intervention consists of 4 modules including test results and explanation of results. The primary endpoint was non-inferiority in change in knowledge and anxiety from baseline to post-disclosure. Secondary analyses evaluated patient-reported outcomes (PROs) such as depression and distress, and moderators of PROs such as socioeconomic status. 229 participants were recruited from 14 states and 37% were male, 17% were non-white, 43% had less than a college education and 21% were from community sites or national recruitment. We met non-inferiority for all short-term PROs for both one visit arms (GC/Digital, Digital/GC). We met non-inferiority for all short-term PROs in the fully digital arm except knowledge which was inconclusive, although differences were small. Uptake of visit 1 was lower in the digital arms, although uptake of testing after visit 1 did not differ between arms. Patients living in poorer areas had greater reductions in anxiety in the visit 1 GC arms and rural patients had greater increase in knowledge in digital arms. Men had greater decreases in anxiety with digital disclosure, while women had greater reductions with GC disclosure. The eREACH patient-centered digital delivery intervention with one GC visit is an evidence-based alternative to two visits with a GC for patients with metastatic cancer. The fully digital model may be acceptable for some patients.


  • Open Access

    An eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Patients With Metastatic Cancers: Protocol for a Randomized Trial

    by Kimberley T Lee, Briana McLeod, Brian Egleston, Sarah Brown, Sarah Howe, Dominique Fetzer, Lauren Gutstein, Cara Cacioppo, Dana Clark, Susan M Domchek, et al.

    Background: Germline BRCA1 and BRCA2 testing is a standard evidence-based practice, with established risk reduction and cancer screening guidelines for genetic carriers. With Food and Drug Administration approval for poly (adenosine diphosphate ribose) polymerase (PARP) inhibitors in patients with metastatic breast, ovarian, pancreatic, and prostate cancer, there is an additional therapeutic rationale for testing all patients with these cancers for germline BRCA1 and BRCA2 mutations. However, many at-risk patients do not have access to genetic services, leaving many genetic carriers unidentified. Objective: The eREACH (A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate, and Pancreatic Cancer Patients) study evaluates the effectiveness of a theoretically and stakeholder-informed eHealth (eg, digital) delivery alternative to traditional genetic counseling for patients with metastatic breast or prostate cancer or advanced or metastatic ovarian or pancreatic cancer referred for genetic testing to determine whether they are candidates for a PARP inhibitor. Methods: The eREACH study is a randomized noninferiority study using a 2 × 2 design to test a self-directed digital intervention to deliver clinical genetic testing for patients with metastatic cancers. The traditional standard-of-care pretest (visit 1) and posttest (visit 2—disclosure) counseling delivered by a genetic counselor is replaced with our patient-informed digital intervention. The four arms were as follows: arm A, genetic counselor for visits 1 and 2; arm B, genetic counselor for visit 1 and digital intervention for visit 2; arm C, digital intervention for visit 1 and genetic counselor for visit 2; and arm D, digital intervention for both visits. Participants were adults with advanced or metastatic breast, ovarian, pancreatic, and prostate cancer. The primary outcomes of this study were change in genetic knowledge and anxiety from baseline to postdisclosure assessment. We will test whether the digital intervention is noninferior to standard-of-care counseling with a genetic counselor using a modified noninferiority ANOVA of the posttest disclosure minus baseline change scores. In secondary analyses, we will test pairwise differences among the 4 groups. Results: As of January 2025, we have completed enrollment of 229 participants. Data analysis is ongoing, and we expect the results to be published in 2025. Conclusions: Increasing indications for BRCA1 and BRCA2 testing create a pressing need to evaluate alternative delivery models to increase access and uptake of these tests while maintaining adequate patient cognitive, affective, and behavioral outcomes. The eREACH study evaluates the effectiveness of an interactive, patient-centered digital intervention to deliver clinical genetic testing to patients with metastatic cancers. We expect that this work will inform evidence-based guidelines and the standard of care for delivery of genetic testing, and it is designed to be broadly applicable and easily adaptable for other populations and settings even beyond oncology. Trial Registration: ClinicalTrials.gov NCT04353973; https://clinicaltrials.gov/study/NCT04353973 International Registered Report Identifier (IRRID): DERR1-10.2196/72515


  • Open Access

    Developing the MyCancerGene Digital Health Portal to Improve Patients’ Understanding of Germline Cancer Genetic Test Results: Development, User, and Usability Testing Study

    by Phillip Trieu, Dominique Fetzer, Briana McLeod, Kathryn Schweickert, Lauren Gutstein, Brian Egleston, Susan Domchek, Linda Fleisher, Lynne Wagner, Kuang-Yi Wen, et al.

    Background: The use of multigene panels has significantly increased the likelihood that genetic testing will leave patients with uncertainties regarding test interpretation, implications, and recommendations, which will change over time. Effective longitudinal care models are needed to provide patients with updated information and to obtain patient and family history updates. Objective: To bridge this gap, we aimed to develop a patient- and genetic provider–informed digital genetic health portal (GHP), MyCancerGene, to improve longitudinal patient understanding of and responses to genetic testing. Methods: We used a 5-step process to develop MyCancerGene. To better understand their interest in and willingness to use a digital GHP, we surveyed 307 patients who completed genetic testing (step 1). We completed qualitative interviews with 10 patients and a focus group with 17 genetic providers to inform the content and function of MyCancerGene (step 2). Next, we developed initial intervention content (step 3) and completed user testing of intervention content with 25 providers and 28 patients (step 4). After developing the prototype intervention, we completed usability testing with 8 patients for their feedback on the final content, functions, and ease of use (step 5). Results: In surveys conducted in step 1, 90% of patients with positive results reported interest in a digital GHP, and over 75% of participants with variants of uncertain significance or uninformative negative results reported similar interest. The most frequently reported advantages among patients were increasing accessibility, convenience, and efficiency (103/224, 46%); keeping genetic information organized (54/224, 24.1%); and increasing or maintaining patient understanding of the information (38/224, 17%). In qualitative interviews (step 2), both patients and genetic providers endorsed the benefit of the tool for updating personal and family history and for providers to share new risk information, test interpretation, or other medical changes. Patient and provider input informed eight key components of the tool: (1) Landing Page, (2) Summary of Care page, (3) My Genetic Test Results page, (4) My Family History page, (5) Provide an Update page, (6) Review an Update page, (7) Resources page, and (8) the Screenings Tracker. They also recommended key functions, including the ability to download and print materials and the inclusion of reminders and engagement functions. Potential challenges identified by patients included privacy and security concerns (67/206, 32.5%) and the potential for electronic information to generate distress (20/206, 9.7%). While patients were comfortable with updates (ie, even variant reclassification upgrades or clinically significant results), 44% (11/25) of genetic providers were uncomfortable sharing variant reclassification upgrades through MyCancerGene. Conclusions: MyCancerGene, a patient-centered digital GHP, was developed with extensive patient and genetic provider feedback and designed to enhance longitudinal patient understanding of and affective and behavioral responses to genetic testing, particularly in the era of evolving evidence and risk information.


  • Open Access

    Patient-centered Evaluation of AI Answers to Genetic Counseling Questions

    by Yidi Huang, Hita Kambhamettu, Elisabeth Wood, Cara Cacioppo, Demetrios Ofidis, Rajia Mim, Angela Bradbury, Kevin Johnson

    The growing use of large language models for health communication raises important questions about patient preferences, trust, and satisfaction with AI-generated content. We conducted a qualitative survey comparing patient perceptions of clinician versus AI answers to questions about Alzheimer’s disease and genetics. Twenty-six participants scored responses on relevance, trustworthiness, and coherence, and additionally selected a preferred response and provided free-text comments. We found that participants generally preferred AI responses over human-written ones and rated them higher on all evaluation axes. Qualitative analysis of free-text comments identified key factors influencing patient preferences, including clarity, verbosity, certainty, empathy, and numeracy, with patients showing diverse and sometimes contradictory preferences along these dimensions. These findings suggest the AI-generated responses were well-received by patients and may have a role in triaging patients with information-seeking queries. Future work should focus on dynamically identifying patient communication preferences and tailoring communication styles accordingly.